血液生物标志物可预测 PD-1 抑制剂治疗乙型肝炎病毒诱导的肝细胞癌患者的生存结局。
Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors.
机构信息
Department of Graduate, Shandong Cancer Hospital and Institute, Shandong First Medical, University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong, First Medical University and Shandong Academy of Medical Sciences, Jinan Shandong, China.
出版信息
J Immunol Res. 2022 Aug 17;2022:3781109. doi: 10.1155/2022/3781109. eCollection 2022.
PURPOSE
To investigate the prognostic value of blood markers in patients with hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) treated with PD-1 inhibitors. . We retrospectively collected and analyzed the clinicopathological data of 110 HBV-induced HCC patients treated with PD-1 inhibitors. Progression-free survival (PFS) and overall survival (OS) were scrutinized using Kaplan-Meier analysis and the log-rank test, and all potential risk factors were analyzed with univariate and multivariate Cox regression analyses.
RESULTS
The mean OS and PFS were 6.5 and 5.5 months, respectively. According to Kaplan-Meier survival curves, elevated systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) correlated with decreased OS and PFS (all < 0.05), and low lymphocyte-to-monocyte ratio (LMR) correlated with decreased PFS and OS (all < 0.05). Per multivariate Cox regression analyses, SII, PLR, and portal vein tumor thrombus (PVTT) correlated independently with PFS (all < 0.05), whereas SII, PLR, NLR, and portal vein tumor thrombus (PVTT) correlated with OS (all < 0.05).
CONCLUSION
SII, PLR, and PVTT predicted OS and PFS in HCC patients who received PD-1 inhibitors and, therefore, could be useful predictors for risk stratification and individualized therapeutic decision-making for patients with HBV-induced HCC treated with PD-1 inhibitors.
目的
研究 PD-1 抑制剂治疗乙型肝炎病毒（HBV）诱导的肝细胞癌（HCC）患者的血液标志物的预后价值。我们回顾性收集并分析了 110 例接受 PD-1 抑制剂治疗的 HBV 诱导的 HCC 患者的临床病理数据。使用 Kaplan-Meier 分析和对数秩检验检查无进展生存期（PFS）和总生存期（OS），并使用单因素和多因素 Cox 回归分析所有潜在的风险因素。
结果
平均 OS 和 PFS 分别为 6.5 个月和 5.5 个月。根据 Kaplan-Meier 生存曲线，升高的全身免疫炎症指数（SII）、血小板与淋巴细胞比值（PLR）和中性粒细胞与淋巴细胞比值（NLR）与 OS 和 PFS 降低相关（均<0.05），而低淋巴细胞与单核细胞比值（LMR）与 PFS 和 OS 降低相关（均<0.05）。多因素 Cox 回归分析显示，SII、PLR 和门静脉癌栓（PVTT）与 PFS 独立相关（均<0.05），而 SII、PLR、NLR 和门静脉癌栓（PVTT）与 OS 相关（均<0.05）。
结论
SII、PLR 和 PVTT 预测了接受 PD-1 抑制剂治疗的 HCC 患者的 OS 和 PFS，因此对于接受 PD-1 抑制剂治疗的 HBV 诱导的 HCC 患者的风险分层和个体化治疗决策可能是有用的预测指标。
Zotero 插件